Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 06 2020
01 06 2020
Historique:
received:
30
01
2020
revised:
12
02
2020
accepted:
18
02
2020
pubmed:
23
2
2020
medline:
7
1
2021
entrez:
23
2
2020
Statut:
ppublish
Résumé
Genomic alterations in DNA damage repair (DDR) genes other than TRITON2 enrolled patients who had progressed on one or two lines of next-generation androgen receptor-directed therapy and one taxane-based chemotherapy for mCRPC. Key endpoints were investigator-assessed radiographic response per modified RECIST/PCWG3 and PSA response (≥50% decrease from baseline). TRITON2 enrolled 78 patients with a non- In this prospective, genomics-driven study of rucaparib in mCRPC, we found limited radiographic/PSA responses to PARP inhibition in men with alterations in
Identifiants
pubmed: 32086346
pii: 1078-0432.CCR-20-0394
doi: 10.1158/1078-0432.CCR-20-0394
pmc: PMC8435354
mid: NIHMS1735834
doi:
Substances chimiques
Indoles
0
Poly(ADP-ribose) Polymerase Inhibitors
0
rucaparib
8237F3U7EH
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
2487-2496Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA092629
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentOn
Informations de copyright
©2020 American Association for Cancer Research.
Références
Nat Biotechnol. 2013 Nov;31(11):1023-31
pubmed: 24142049
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Cell. 2018 Jun 14;173(7):1770-1782.e14
pubmed: 29906450
Nucleic Acids Res. 2015 Mar 11;43(5):2575-89
pubmed: 25712099
J Clin Med. 2019 Mar 30;8(4):
pubmed: 30934991
J Mol Cell Biol. 2014 Dec;6(6):442-57
pubmed: 25404613
Breast Cancer Res Treat. 2017 Jun;163(2):383-390
pubmed: 28281021
Cancer Res. 2014 Jan 1;74(1):287-97
pubmed: 24240700
Lancet Oncol. 2020 Jan;21(1):162-174
pubmed: 31806540
Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2):
pubmed: 30833416
N Engl J Med. 2015 Oct 29;373(18):1697-708
pubmed: 26510020
Eur Urol. 2019 Oct;76(4):452-458
pubmed: 30797618
J Mol Diagn. 2018 Sep;20(5):686-702
pubmed: 29936259
BioDrugs. 2019 Jun;33(3):255-273
pubmed: 30895466
Hum Mol Genet. 2002 Oct 1;11(21):2591-7
pubmed: 12354784
Mol Cancer Res. 2009 Jul;7(7):1110-8
pubmed: 19584259
JCO Precis Oncol. 2020;4:370-381
pubmed: 32462107
Cancer Discov. 2017 Sep;7(9):1006-1017
pubmed: 28450425
J Mol Diagn. 2019 Jul;21(4):646-657
pubmed: 31201024
J Biol Chem. 2014 Mar 28;289(13):9247-53
pubmed: 24554720
J Natl Cancer Inst. 2018 Sep 1;110(9):1030-1034
pubmed: 29506079